IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs ALT 803 (Primary) ; ALT 803 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 20 Feb 2018 Results (n=33) published in the Blood
- 23 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 23 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.